Krystal Biotech (KRYS) Total Liabilities (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Total Liabilities of $141.5 million for Q2 2026, up 44.78% year-over-year from $97.7 million in Q2 2025, and up 17.7% on a QoQ basis from $120.2 million in Q1 2026.
Krystal Biotech (KRYS) Total Liabilities (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Total Liabilities for 11 years, with the latest figure at $141.5 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $141.5 million, up 44.78% year-over-year; the trailing twelve-month figure through Jun 2026 was $141.5 million (up 44.78% YoY), and the FY2025 annual result was $114.2 million, up 4.36% from the prior year.
- Total Liabilities improved to $141.5 million in Q2 2026, from $120.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $141.5 million in Q2 2026 and troughed at $30.9 million in Q2 2023.
- A 5-year average of $74.1 million and a median of $73.5 million in 2022 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities jumped 452.48%; it then sank 38.11% in 2023.
- A 5-year view of Total Liabilities shows it stood at $36.2 million in 2022, then climbed by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then advanced by 4.36% to $114.2 million in 2025, then gained by 23.89% to $141.5 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $141.5 million in Q2 2026, $120.2 million in Q1 2026, and $114.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 141.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 141.52 Mn |
| Mar 31, 2026 | 120.24 Mn |
| Dec 31, 2025 | 114.23 Mn |
| Sep 30, 2025 | 102.22 Mn |
| Jun 30, 2025 | 97.75 Mn |
| Mar 31, 2025 | 89.74 Mn |
| Dec 31, 2024 | 109.46 Mn |
| Sep 30, 2024 | 96.47 Mn |
| Jun 30, 2024 | 78.77 Mn |
| Mar 31, 2024 | 54.05 Mn |
| Dec 31, 2023 | 39.71 Mn |
| Sep 30, 2023 | 34.40 Mn |
| Jun 30, 2023 | 30.91 Mn |
| Mar 31, 2023 | 42.28 Mn |
| Dec 31, 2022 | 36.22 Mn |
| Sep 30, 2022 | 35.61 Mn |
| Jun 30, 2022 | 42.14 Mn |
| Mar 31, 2022 | 68.32 Mn |
| Dec 31, 2021 | 32.72 Mn |
| Sep 30, 2021 | 42.86 Mn |